Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Hye Won Lee, Jun Yong Park & Sang Hoon Ahn. (2016) An evaluation of entecavir for the treatment of chronic hepatitis B infection in adults. Expert Review of Gastroenterology & Hepatology 10:2, pages 177-186.
Read now
Read now
Jörg Petersen & Maria Buti. (2012) Considerations for the long-term treatment of chronic hepatitis B with nucleos(t)ide analogs. Expert Review of Gastroenterology & Hepatology 6:6, pages 683-694.
Read now
Read now
Ezequiel Ridruejo & Marcelo O Silva. (2012) Safety of long-term nucleos(t)ide treatment in chronic hepatitis B. Expert Opinion on Drug Safety 11:3, pages 357-360.
Read now
Read now
Articles from other publishers (44)
琳 杨. (2023) Clinical Research on LLV Patients with Chronic Hepatitis B. Advances in Clinical Medicine 13:08, pages 13038-13044.
Crossref
Crossref
Mingdi Liu, Peng Shi, Guangle Wang, Gang Wang, Ping Song, Yumin Liu, Songgu Wu & Junbo Gong. (2021) Quantitative analysis of binary mixtures of entecavir using solid-state analytical techniques with chemometric methods. Arabian Journal of Chemistry 14:10, pages 103360.
Crossref
Crossref
Andrew Vaillant. (2021) Transaminase Elevations during Treatment of Chronic Hepatitis B Infection: Safety Considerations and Role in Achieving Functional Cure. Viruses 13:5, pages 745.
Crossref
Crossref
Jonggi Choi & Young-Suk Lim. 2021. Hepatitis B Virus and Liver Disease. Hepatitis B Virus and Liver Disease
287
318
.
Anaïs Brayette, Marie Essig, Paul Carrier, Marilyne Debette-Gratien, Anaïs Labrunie, Sophie Alain, Marianne Maynard, Nathalie Ganne-Carrié, Eric Nguyen-Khac, Pauline Pinet, Victor De Ledinghen, Christophe Renou, Philippe Mathurin, Claire Vanlemmens, Vincent Di Martino, Anne Gervais, Juliette Foucher, Fouchard-Hubert Isabelle, Julien Vergniol, Isabelle Hourmand-Ollivier, Daniel Cohen, Xavier Duval, Thierry Poynard, Marc Bardou, Armand Abergel, Manh-Thong Dao, Thierry Thévenot, Jean-Baptiste Hiriart, Valérie Canva, Guillaume Lassailly, Christine Aurières, Nathalie Boyer, Dominique Thabut, Pierre-Henri Bernard, Matthieu Schnee, Dominique Larrey, Bertrand Hanslik, Séverine Hommel, Jérémie Jacques & Véronique Loustaud-Ratti. (2020) Subclinical proximal tubulopathy in hepatitis B: The roles of nucleot(s)ide analogue treatment and the hepatitis B virus. World Journal of Hepatology 12:12, pages 1326-1340.
Crossref
Crossref
Minseok Albert Kim, Seung Up Kim, Dong Hyun Sinn, Jeong Won Jang, Young-Suk Lim, Sang Hoon Ahn, Jae-Jun Shim, Yeon Seok Seo, Yang Hyun Baek, Sang Gyune Kim, Young Seok Kim, Ji Hoon Kim, Won Hyeok Choe, Hyung Joon Yim, Hyun Woong Lee, Jung Hyun Kwon, Sung Won Lee, Jae Young Jang, Hwi Young Kim, Yewan Park, Gi-Ae Kim, Hyun Yang, Han Ah Lee, Myeongseok Koh, Young-Sun Lee, Minkoo Kim, Young Chang, Yoon Jun Kim, Jung-Hwan Yoon, Fabien Zoulim & Jeong-Hoon Lee. (2020) Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. Gut 69:12, pages 2214-2222.
Crossref
Crossref
Fang Xiong, Xuli Bao, Na Gu, Jia Guo, Jinhuan Wang, Yanpin Ma, Lele Yu, Yao Gao, Bingqin Tan & Jun Lu. (2020) The combination therapy of Peginterferonα and entecavir for HBeAg-positive chronic hepatitis B with high HCC risk. Infection, Genetics and Evolution 78, pages 104101.
Crossref
Crossref
Marc Bourlière & Stanislas Pol. (2019) Abstracts. Liver International 39:12, pages 2420-2468.
Crossref
Crossref
Annamaria Mechtler, Nahla H. Ahmed, Jo Ann Wheeler & Alexei Gonzalez-Estrada. (2019) Oral desensitization to entecavir. Annals of Allergy, Asthma & Immunology 123:3, pages 312-313.
Crossref
Crossref
Aoran Luo, Xiaoyan Jiang & Hong Ren. (2018) Entecavir-based combination therapies for chronic hepatitis B. Medicine 97:51, pages e13596.
Crossref
Crossref
Xiaojuan Wang, Hai-Jiang Xu, Xue-Dong Jia, Yan-Tao Yang & Xiao-Jian Zhang. (2018) Crystal structure and Hirshfeld surface analysis of the anhydrous form of the nucleoside analogue entecavir. Acta Crystallographica Section C Structural Chemistry 74:3, pages 381-385.
Crossref
Crossref
Maria Buti, Mar Riveiro-Barciela & Rafael Esteban. (2018) Long-term safety and efficacy of nucleo(t)side analogue therapy in hepatitis B. Liver International 38, pages 84-89.
Crossref
Crossref
Chang Wook Kim, Chang Seop Kim, Hee Yeon Kim, Chang Don Lee, Kyungha Yu, Cyril Llamoso & Heon Ju Lee. (2018) Large-scale surveillance study of the safety and effectiveness of entecavir in Korean patients with chronic hepatitis B. The Korean Journal of Internal Medicine 33:1, pages 91-101.
Crossref
Crossref
Jonggi Choi & Young-Suk Lim. 2018. Hepatitis B Virus and Liver Disease. Hepatitis B Virus and Liver Disease
193
217
.
Hong Joo Kim, Yong Kyun Cho, Woo Kyu Jeon & Byung Ik Kim. (2017) Clinical characteristics of patients with chronic hepatitis B who developed genotypic resistance to entecavir: Real-life experience. Clinical and Molecular Hepatology 23:4, pages 323-330.
Crossref
Crossref
Hee Yeon Seo, Han Ah Lee, Soon Young Ko, Joon Ho Wang, Jeong Han Kim, Won Hyeok Choe & So Young Kwon. (2017) Clinical impact of the early alanine amininotransferase flare during tenofovir monotherapy in treatment-na?ve patients with chronic hepatitis B. Clinical and Molecular Hepatology 23:2, pages 154-159.
Crossref
Crossref
Tassanee Sriprayoon, Chulabhorn Mahidol, Teerapat Ungtrakul, Pattra Chun-on, Kamonwan Soonklang, Wanvisa Pongpun, Charlie Laohapand, Jiraporn Dechma, Charinthip Pothijaroen, Chirayu Auewarakul & Tawesak Tanwandee. (2017) Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: A randomized controlled trial. Hepatology Research 47:3, pages E161-E168.
Crossref
Crossref
Bircan Kayaaslan & Rahmet Guner. (2017) Adverse effects of oral antiviral therapy in chronic hepatitis B. World Journal of Hepatology 9:5, pages 227.
Crossref
Crossref
Heng Chi, Pauline Arends, Jurri?n G P Reijnders, Ivana Carey, Ashley Brown, Massimo Fasano, David Mutimer, Katja Deterding, Ye H Oo, J?rg Petersen, Florian van Bommel, Robert J de Knegt, Teresa A Santantonio, Thomas Berg, Tania M Welzel, Heiner Wedemeyer, Maria Buti, Pierre Pradat, Fabien Zoulim, Bettina E Hansen & Harry L A Janssen. (2016) Flares during long-term entecavir therapy in chronic hepatitis B. Journal of Gastroenterology and Hepatology 31:11, pages 1882-1887.
Crossref
Crossref
Ruma Rajbhandari & Raymond T Chung. (2016) Treatment of Hepatitis B: A Concise Review. Clinical and Translational Gastroenterology 7:9, pages e190.
Crossref
Crossref
Xiaoli Fan, Liyu Chen, Jingyu Yang & Ping Feng. (2016) Entecavir-Associated Thrombocytopenia in a Decompensated Cirrhotic Patient. Medicine 95:12, pages e3103.
Crossref
Crossref
Ji Hyun SongSi Yeon KimJae Kyoung ShinSo Dam HongKyu Sung RimHa Na ParkJoo Ho LeeYun Bin LeeSeung Hun OhSeong Gyu Hwang. (2016) A Case of Severe Peripheral Polyneuropathy Occurring after Entecavir Treatment in a Hepatitis B Patient. The Korean Journal of Gastroenterology 67:4, pages 216.
Crossref
Crossref
J. Ahn, H. M. Lee, J. K. Lim, C. Q. Pan, M. H. Nguyen, W. Ray Kim, A. Mannalithara, H. Trinh, D. Chu, T. Tran, A. Min, S. Do, H. Te, K. R. Reddy & A. S. Lok. (2015)
Entecavir safety and effectiveness in a national cohort of treatment‐naïve chronic hepatitis B patients in the
US
– the
ENUMERATE
study
. Alimentary Pharmacology & Therapeutics 43:1, pages 134-144.
Crossref
Crossref
Mauro Viganò, Massimo Puoti & Pietro Lampertico. 2016. Hepatitis B Virus in Human Diseases. Hepatitis B Virus in Human Diseases
339
359
.
Paul Martin, Daryl T.-Y. Lau, Mindie H. Nguyen, Harry L.A. Janssen, Douglas T. Dieterich, Marion G. Peters & Ira M. Jacobson. (2015) A Treatment Algorithm for the Management of Chronic Hepatitis B Virus Infection in the United States: 2015 Update. Clinical Gastroenterology and Hepatology 13:12, pages 2071-2087.e16.
Crossref
Crossref
Grace Lai‐Hung Wong, Yee‐Kit Tse, Vincent Wai‐Sun Wong, Terry Cheuk‐Fung Yip, Kelvin Kam‐Fai Tsoi & Henry Lik‐Yuen Chan. (2015) Long‐term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects. Hepatology 62:3, pages 684-693.
Crossref
Crossref
F. van B?mmel & T. Berg. (2015) Langzeittherapie der HBV-Infektion mit oralen PolymeraseinhibitorenLong-term treatment of HBV infection with oral polymerase inhibitors. Der Gastroenterologe 10:4, pages 268-283.
Crossref
Crossref
Scott Bowden, Stephen Locarnini, Ting-Tsung Chang, You-Chen Chao, Kwang-Hyub Han, Robert G Gish, Robert A de Man, Miao Yu, Cyril Llamoso & Hong Tang. (2015) Covalently closed-circular hepatitis B virus DNA reduction with entecavir or lamivudine. World Journal of Gastroenterology 21:15, pages 4644-4651.
Crossref
Crossref
Mauro Viganò, Federica Invernizzi & Pietro Lampertico. (2014) Optimal therapy of chronic hepatitis B: how do I treat my HBeAg‐negative patients?. Liver International 35:s1, pages 107-113.
Crossref
Crossref
Maria Buti, Rosa M. Morillas, Juan Pérez, Martín Prieto, Ricard Solà, Antonio Palau, Moisés Diago, Lucía Bonet, Adolfo Gallego, Javier García-Samaniego, Milagros Testillano, Manuel Rodríguez, Gregorio Castellano, María L. Gutiérrez, Manuel Delgado, Antoni Mas, Manuel Romero-Gómez, José L. Calleja, Agustina González-Guirado, Juan I. Arenas, Luisa García-Buey, Raúl Andrade & Ana Gila. (2015) Entecavir has high efficacy and safety in white patients with chronic hepatitis B and comorbidities. European Journal of Gastroenterology & Hepatology 27:1, pages 46-54.
Crossref
Crossref
Fabien Zoulim, Giampiero Carosi, Susan Greenbloom, Wlodzimierz Mazur, Tuan Nguyen, Lennox Jeffers, Maurizia Brunetto, Song Yu & Cyril Llamoso. (2015) Quantification of HBsAg in nucleos(t)ide-na?ve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study. Journal of Hepatology 62:1, pages 56-63.
Crossref
Crossref
Ezequiel Ridruejo, Sebastián Marciano, Omar Galdame, María V. Reggiardo, Alberto E. Muñoz, Raúl Adrover, Daniel Cocozzella, Nora Fernandez, Claudio Estepo, Manuel Mendizabal, Gustavo A. Romero, Diana Levi, Teresa Schroder, Silvia Paz, Hugo Fainboim, Oscar G. Mandó, Adrián C. Gadano & Marcelo O. Silva. (2014) Efficacy and safety of long term entecavir in chronic hepatitis B treatment naïve patients in clinical practice. Annals of Hepatology 13:3, pages 327-336.
Crossref
Crossref
Kalman Tokes, Syed Quadri, Patrick Cahill, Grace Chiu, Angel Ivanov & Hong Tang. (2013) Disease and Treatment Perceptions Among Asian Americans Diagnosed with Chronic Hepatitis B Infection. Journal of General Internal Medicine 29:3, pages 477-484.
Crossref
Crossref
Mauro Viganò, Giampaolo Mangia & Pietro Lampertico. (2013)
HB
eAg‐negative chronic hepatitis B: why do I treat my patients with nucleos(t)ide analogues?
. Liver International 34:s1, pages 120-126.
Crossref
Crossref
Jeong Tae Kim. (2014) Delayed hypersensitivity reaction resulting in maculopapular-type eruption due to entecavir in the treatment of chronic hepatitis B. World Journal of Gastroenterology 20:42, pages 15931.
Crossref
Crossref
Isobel D. Ramsay, Jodi M. Lestner, Catherine P. O’Sullivan, Ana L.G. Cruz, Ho Kwong Li & Charlotte I.S. Barker. 2014. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions
401
443
.
Michael C. Kew. 2014. Viruses and Human Cancer. Viruses and Human Cancer
133
165
.
J.‐L. Hou, J.‐D. Jia, L. Wei, W. Zhao, Y. M. Wang, M. Cheng, X. Tang, D.‐M. Tan, H. Ren, H. Tang, D. Cohen & C. Llamoso. (2013)
Efficacy and safety of entecavir treatment in a heterogeneous
CHB
population from a ‘real‐world’ clinical practice setting in
C
hina
. Journal of Viral Hepatitis 20:11, pages 811-820.
Crossref
Crossref
Calvin Q Pan, Ke-Qin Hu & Naoky Tsai. (2013) Long-Term Therapy with Nucleoside/Nucleotide Analogues for Chronic Hepatitis B in Asian Patients. Antiviral Therapy 18:7, pages 841-852.
Crossref
Crossref
Robert Perrillo, Maria Buti, Francois Durand, Michael Charlton, Adrian Gadano, Guido Cantisani, Che‐Chuan Loong, Kimberly Brown, Wenhua Hu, Juan Carlos Lopez‐Talavera & Cyril Llamoso. (2013) Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. Liver Transplantation 19:8, pages 887-895.
Crossref
Crossref
Patrick Marcellin & Tarik Asselah. (2013) Long-term therapy for chronic hepatitis B: Hepatitis B virus DNA suppression leading to cirrhosis reversal. Journal of Gastroenterology and Hepatology 28:6, pages 912-923.
Crossref
Crossref
Ashrafali Mohamed Ismail, Om Prakash Sharma, Muthuvel Suresh Kumar, Chundamanil Eapen Eapen, Rajesh Kannangai & Priya Abraham. (2013) Virological response and antiviral resistance mutations in chronic hepatitis B subjects experiencing entecavir therapy: An Indian subcontinent perspective. Antiviral Research 98:2, pages 209-216.
Crossref
Crossref
Anna S. Lok, Huy Trinh, Giampiero Carosi, Ulus S. Akarca, Adrian Gadano, François Habersetzer, William Sievert, David Wong, Meghan Lovegren, David Cohen & Cyril Llamoso. (2012) Efficacy of Entecavir With or Without Tenofovir Disoproxil Fumarate for Nucleos(t)ide-Naïve Patients With Chronic Hepatitis B. Gastroenterology 143:3, pages 619-628.e1.
Crossref
Crossref
Calvin Q. Pan, Myron Tong, Kris V. Kowdley, Ke–Qin Hu, Ting–Tsung Chang, Ching–Lung Lai, Seung Kew Yoon, Samuel S. Lee, David Cohen, Hong Tang & Naoky Tsai. (2012) High Rates of Viral Suppression After Long-term Entecavir Treatment of Asian Patients With Hepatitis B e Antigen–Positive Chronic Hepatitis B. Clinical Gastroenterology and Hepatology 10:9, pages 1047-1050.e1.
Crossref
Crossref